The first commercial application of the Visby Medical single-use, rapid PCR platform received FDA EUA in 2020 for COVID-19 testing. Currently under review with the FDA is a multiplex assay for Chlamydia, Gonorrhea, and Trichomonas from a single sample, at the point of care.